8-K: Tonix Pharmaceuticals Announces Positive Preclinical Data for TNX-1500, Supporting Monthly Dosing

Tonix Pharmaceuticals' TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, shows promising pharmacokinetic properties in animal studies, suggesting a three-week half-life in humans and supporting monthly dosing.

Summary

• Tonix Pharmaceuticals has announced the results of modeling key human pharmacokinetic (PK) properties for their drug candidate TNX-1500 based on animal studies.
• The modeling predicts a half-life of approximately three weeks for TNX-1500 in humans, which supports monthly dosing.
• The PK study was conducted in six healthy cynomolgus monkeys at 30, 100 and 300 mg/kg, revealing linear PK across those doses.
• The half-life of TNX-1500 in cynomolgus monkeys is approximately 14 days.
• The predicted human half-life for TNX-1500 is 23.8 days, with a range of 18.3 to 27.6 days.
• Clearance in cynomolgus animals was 6.24 ml/day, and the predicted clearance in humans was 141 mL/day.
• The company expects the results of the Phase 1 PK and pharmacodynamic trial in the third quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents positive preclinical data for TNX-1500, supporting monthly dosing and highlighting its potential in transplantation and autoimmune diseases. However, it also acknowledges the risks associated with drug development and regulatory approval.

Positives

• The predicted three-week half-life of TNX-1500 in humans supports convenient monthly dosing.
• TNX-1500 has shown linear PK across different doses in animal studies, indicating predictable drug behavior.
• The protein engineering of TNX-1500's Fc region appears to have achieved its design goals, reducing thrombosis risk.
• The company has completed the clinical phase of the Phase 1 trial, with results expected in the third quarter of 2024.
• TNX-1500 has multiple potential indications, including solid organ and bone marrow transplantation and the treatment of autoimmune diseases.

Negatives

• No anti-CD40L mAb has been approved in any jurisdiction, indicating a challenging regulatory path.
• The company is still in the early stages of clinical development for TNX-1500, with Phase 2 trials yet to commence.
• The success of TNX-1500 is dependent on the results of the Phase 1 trial and subsequent clinical trials.

Risks

• The company faces risks related to obtaining FDA clearances or approvals for its products.
• There are risks related to the timing and progress of clinical development of product candidates.
• The company has a need for additional financing to support its operations.
• There are uncertainties of patent protection and litigation.
• The company faces substantial competition in the pharmaceutical industry.

Future Outlook

The company anticipates the results of the Phase 1 PK and pharmacodynamic trial in the third quarter of 2024 and plans to advance TNX-1500 as a promising candidate for prevention of organ and bone marrow transplant rejection and for treating autoimmune conditions.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that anti-CD40L therapy has shown promise in transplantation and the treatment of autoimmunity for more than 30 years.
• Dr. Lederman also noted that TNX-1500 maintains the activity of first-generation mAbs with reduced risk of thrombotic complications.
• Dr. Lederman mentioned that the company looks forward to the results of the Phase 1 trial and advancing TNX-1500.

Industry Context

The announcement highlights the competitive landscape in anti-CD40L therapeutics, with Sanofi's frexalimab and Eledon Pharmaceuticals' tegoprubart also in development. The success of TNX-1500 could position Tonix as a key player in this space.

Comparison to Industry Standards

• Sanofi's frexalimab, a similar Fc-modified anti-CD40L mAb, is projected to reach peak sales of over 5B per year, indicating the potential market size for this class of drugs.
• Eledon Pharmaceuticals' tegoprubart is in Phase 2 development for kidney transplant rejection, representing a direct competitor in the transplantation space.
• The predicted human half-life of 23.8 days for TNX-1500 is comparable to other mAbs with linear PK, supporting monthly dosing.

Stakeholder Impact

• Shareholders may view the positive preclinical data as a positive development for the company.
• Patients with autoimmune diseases and those needing organ transplants may benefit from the development of TNX-1500.
• Employees of Tonix Pharmaceuticals may be impacted by the progress of the drug development program.

Next Steps

• The company expects the results of the Phase 1 PK and pharmacodynamic trial in the third quarter of 2024.
• The company plans to advance TNX-1500 as a promising candidate for prevention of organ and bone marrow transplant rejection and for treating autoimmune conditions.

Key Dates

Keywords

TNX-1500, anti-CD40L, monoclonal antibody, pharmacokinetics, transplantation, autoimmune, clinical trial, half-life, monthly dosing, Fc-modified